Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Pyrrolidines"" wg kryterium: Temat


Tytuł :
Improved SARS-CoV-2 M inhibitors based on feline antiviral drug GC376: Structural enhancements, increased solubility, and micellar studies.
Autorzy :
Vuong W; Department of Chemistry, University of Alberta, Edmonton AB, T6G 2G2, Canada.
Fischer C; Department of Chemistry, University of Alberta, Edmonton AB, T6G 2G2, Canada.
Khan MB; Department of Biochemistry, Membrane Protein Disease Research Group, University of Alberta, Edmonton AB, T6G 2R3, Canada.
van Belkum MJ; Department of Chemistry, University of Alberta, Edmonton AB, T6G 2G2, Canada.
Lamer T; Department of Chemistry, University of Alberta, Edmonton AB, T6G 2G2, Canada.
Willoughby KD; Department of Chemistry, University of Alberta, Edmonton AB, T6G 2G2, Canada.
Lu J; Department of Biochemistry, Membrane Protein Disease Research Group, University of Alberta, Edmonton AB, T6G 2R3, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton AB, T6G 2E1, Canada.
Arutyunova E; Department of Biochemistry, Membrane Protein Disease Research Group, University of Alberta, Edmonton AB, T6G 2R3, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton AB, T6G 2E1, Canada.
Joyce MA; Department of Medical Microbiology and Immunology, University of Alberta, Edmonton AB, T6G 2R3, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton AB, T6G 2E1, Canada.
Saffran HA; Department of Medical Microbiology and Immunology, University of Alberta, Edmonton AB, T6G 2R3, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton AB, T6G 2E1, Canada.
Shields JA; Department of Medical Microbiology and Immunology, University of Alberta, Edmonton AB, T6G 2R3, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton AB, T6G 2E1, Canada.
Young HS; Department of Biochemistry, Membrane Protein Disease Research Group, University of Alberta, Edmonton AB, T6G 2R3, Canada.
Nieman JA; Department of Medical Microbiology and Immunology, University of Alberta, Edmonton AB, T6G 2R3, Canada; Li Ka Shing Applied Virology Institute, University of Alberta, Edmonton AB, T6G 2E1, Canada.
Tyrrell DL; Department of Medical Microbiology and Immunology, University of Alberta, Edmonton AB, T6G 2R3, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton AB, T6G 2E1, Canada.
Lemieux MJ; Department of Biochemistry, Membrane Protein Disease Research Group, University of Alberta, Edmonton AB, T6G 2R3, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton AB, T6G 2E1, Canada.
Vederas JC; Department of Chemistry, University of Alberta, Edmonton AB, T6G 2G2, Canada. Electronic address: .
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2021 Oct 15; Vol. 222, pp. 113584. Date of Electronic Publication: 2021 May 30.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antiviral Agents/*pharmacology
Coronavirus 3C Proteases/*antagonists & inhibitors
Cysteine Proteinase Inhibitors/*pharmacology
Pyrrolidines/*pharmacology
SARS-CoV-2/*drug effects
Sulfonic Acids/*pharmacology
Animals ; Antiviral Agents/chemical synthesis ; Antiviral Agents/metabolism ; Binding Sites ; Chlorocebus aethiops ; Coronavirus 3C Proteases/chemistry ; Coronavirus 3C Proteases/metabolism ; Crystallography, X-Ray ; Cysteine Proteinase Inhibitors/chemical synthesis ; Cysteine Proteinase Inhibitors/metabolism ; Humans ; Micelles ; Microbial Sensitivity Tests ; Molecular Structure ; Protein Binding ; Pyrrolidines/chemical synthesis ; Pyrrolidines/metabolism ; SARS-CoV-2/enzymology ; Solubility ; Structure-Activity Relationship ; Sulfonic Acids/chemical synthesis ; Sulfonic Acids/metabolism ; Vero Cells
Czasopismo naukowe
Tytuł :
Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results.
Autorzy :
Mistry PK; Yale University School of Medicine, New Haven, Connecticut, USA.
Lukina E; National Research Center for Hematology, Moscow, Russia.
Ben Turkia H; Hôpital La Rabta, Tunis, Tunisia.
Shankar SP; Emory University, Atlanta, Georgia, USA.
Baris Feldman H; The Genetics Institute, Tel Aviv Sourasky Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Ghosn M; Hôtel-Dieu de France University Hospital, Beirut, Lebanon.
Mehta A; The Royal Free Hospital, London, UK.
Packman S; UCSF School of Medicine, San Francisco, California, USA.
Lau H; New York University School of Medicine, New York, New York, USA.
Petakov M; Clinical Center of Serbia, Belgrade University Medical School, Belgrade, Serbia.
Assouline S; Jewish General Hospital, Montreal, Quebec, Canada.
Balwani M; Icahn School of Medicine at Mt. Sinai Hospital, New York, New York, USA.
Danda S; Christian Medical College, Vellore, India.
Hadjiev E; University Hospital Alexandrovska, Sofia, Bulgaria.
Ortega A; OCA Hospital, Monterrey, Mexico.
Foster MC; Sanofi Genzyme, Cambridge, Massachusetts, USA.
Gaemers SJM; Sanofi Genzyme, Amsterdam, The Netherlands.
Peterschmitt MJ; Sanofi Genzyme, Cambridge, Massachusetts, USA.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2021 Sep 01; Vol. 96 (9), pp. 1156-1165. Date of Electronic Publication: 2021 Jul 11.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Enzyme Inhibitors/*therapeutic use
Gaucher Disease/*drug therapy
Pyrrolidines/*therapeutic use
Adult ; Double-Blind Method ; Enzyme Inhibitors/adverse effects ; Female ; Gaucher Disease/pathology ; Humans ; Liver/drug effects ; Liver/pathology ; Male ; Organ Size/drug effects ; Placebo Effect ; Pyrrolidines/adverse effects ; Spleen/drug effects ; Spleen/pathology ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Pyrrolidine in Drug Discovery: A Versatile Scaffold for Novel Biologically Active Compounds.
Autorzy :
Li Petri G; Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi 32, 90123, Palermo, Italy.
Raimondi MV; Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi 32, 90123, Palermo, Italy. .
Spanò V; Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi 32, 90123, Palermo, Italy.
Holl R; Department of Chemistry, Institute of Organic Chemistry, University of Hamburg, Martin-Luther-King-Platz 6, 20146, Hamburg, Germany.
Barraja P; Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi 32, 90123, Palermo, Italy.
Montalbano A; Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi 32, 90123, Palermo, Italy.
Pokaż więcej
Źródło :
Topics in current chemistry (Cham) [Top Curr Chem (Cham)] 2021 Aug 10; Vol. 379 (5), pp. 34. Date of Electronic Publication: 2021 Aug 10.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Drug Discovery*
Pyrrolidines/*chemistry
Humans ; Molecular Structure ; Pyrrolidines/chemical synthesis ; Stereoisomerism
Czasopismo naukowe
Tytuł :
DBPR108, a novel dipeptidyl peptidase-4 inhibitor with antihyperglycemic activity.
Autorzy :
Yeh KC; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, Taiwan.
Yeh TK; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, Taiwan. Electronic address: .
Huang CY; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, Taiwan.
Hu CB; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, Taiwan.
Wang MH; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, Taiwan.
Huang YW; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, Taiwan.
Chou LH; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, Taiwan.
Ho HH; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, Taiwan.
Song JS; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, Taiwan.
Hsu T; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, Taiwan.
Jiaang WT; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, Taiwan.
Chao YS; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, Taiwan.
Chen CT; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, Taiwan. Electronic address: .
Pokaż więcej
Źródło :
Life sciences [Life Sci] 2021 Aug 01; Vol. 278, pp. 119574. Date of Electronic Publication: 2021 May 05.
Typ publikacji :
Journal Article
MeSH Terms :
Butanes/*pharmacology
Dipeptidyl-Peptidase IV Inhibitors/*pharmacology
Hyperglycemia/*drug therapy
Hypoglycemic Agents/*pharmacology
Nitriles/*pharmacology
Pyrrolidines/*pharmacology
Administration, Oral ; Animals ; Area Under Curve ; Body Weight ; Butanes/pharmacokinetics ; Diabetes Mellitus, Experimental/drug therapy ; Dipeptidyl Peptidase 4/chemistry ; Dipeptidyl-Peptidase IV Inhibitors/pharmacokinetics ; Dogs ; Glucose Tolerance Test ; Hypoglycemic Agents/pharmacokinetics ; Insulin/metabolism ; Jugular Veins/pathology ; Male ; Metformin ; Mice ; Mice, Inbred C57BL ; Mice, Obese ; Nitriles/pharmacokinetics ; Pyrrolidines/pharmacokinetics ; Rats ; Rats, Sprague-Dawley ; Species Specificity
Czasopismo naukowe
Tytuł :
Effect of the novel dual orexin receptor antagonist daridorexant on night-time respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease.
Autorzy :
Boof ML; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
Dingemanse J; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
Brunke M; Klinische Forschung Hannover-Mitte GmbH, Hannover, Germany.
Esselmann A; Zentrum für Medizinische Studien GmbH, Warendorf, Germany.
Heymer P; Klinische Forschung Dresden GmbH, Dresden, Germany.
Kestermann O; framol-med GmbH Lungenpraxis Rheine, Rheine, Germany.
Lederer K; Advanced Sleep Research, Berlin, Germany.
Fietze I; Advanced Sleep Research, Berlin, Germany.
Ufer M; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
Pokaż więcej
Źródło :
Journal of sleep research [J Sleep Res] 2021 Aug; Vol. 30 (4), pp. e13248. Date of Electronic Publication: 2021 Jan 08.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Imidazoles/*therapeutic use
Orexin Receptor Antagonists/*therapeutic use
Pulmonary Disease, Chronic Obstructive/*drug therapy
Pulmonary Disease, Chronic Obstructive/*physiopathology
Pyrrolidines/*therapeutic use
Respiration/*drug effects
Sleep/*drug effects
Adolescent ; Adult ; Aged ; Cross-Over Studies ; Double-Blind Method ; Female ; Humans ; Imidazoles/pharmacology ; Male ; Middle Aged ; Orexin Receptor Antagonists/administration & dosage ; Orexin Receptor Antagonists/pharmacology ; Pulmonary Disease, Chronic Obstructive/complications ; Pyrrolidines/pharmacology ; Young Adult
Czasopismo naukowe
Tytuł :
Small-Molecule Inhibitors Targeting Proteasome-Associated Deubiquitinases.
Autorzy :
Moon S; Department of New Biology, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu 42988, Korea.; Protein Dynamics-Based Proteotoxicity Control Lab, Basic Research Lab, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu 42988, Korea.; Center for Cell Fate Reprogramming & Control, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu 42988, Korea.
Muniyappan S; Department of New Biology, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu 42988, Korea.
Lee SB; Protein Dynamics-Based Proteotoxicity Control Lab, Basic Research Lab, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu 42988, Korea.; Department of Brain & Cognitive Sciences, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu 42988, Korea.
Lee BH; Department of New Biology, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu 42988, Korea.; Protein Dynamics-Based Proteotoxicity Control Lab, Basic Research Lab, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu 42988, Korea.; Center for Cell Fate Reprogramming & Control, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu 42988, Korea.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Jun 09; Vol. 22 (12). Date of Electronic Publication: 2021 Jun 09.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Enzyme Inhibitors*/chemistry
Enzyme Inhibitors*/therapeutic use
Neoplasm Proteins*/antagonists & inhibitors
Neoplasm Proteins*/metabolism
Neoplasms*/drug therapy
Neoplasms*/enzymology
Neoplasms*/pathology
Pyrroles*/chemistry
Pyrroles*/therapeutic use
Pyrrolidines*/chemistry
Pyrrolidines*/therapeutic use
Ubiquitin Thiolesterase*/antagonists & inhibitors
Ubiquitin Thiolesterase*/metabolism
Proteasome Endopeptidase Complex/*metabolism
Proteolysis/*drug effects
Humans
Czasopismo naukowe
Tytuł :
Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study.
Autorzy :
Takahashi S; The Cancer Institute Hospital of JFCR, Tokyo, Japan.
Fujiwara Y; Department of Respiratory Medicine, Mitsui Memorial Hospital, Tokyo, Japan.; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
Nakano K; The Cancer Institute Hospital of JFCR, Tokyo, Japan.
Shimizu T; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
Tomomatsu J; The Cancer Institute Hospital of JFCR, Tokyo, Japan.
Koyama T; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
Ogura M; The Cancer Institute Hospital of JFCR, Tokyo, Japan.
Tachibana M; Quantitative Clinical Pharmacology Pharmacokinetics Department, Daiichi Sankyo Co., Ltd, Tokyo, Japan.
Kakurai Y; Data Intelligence Department, Daiichi Sankyo Co., Ltd, Tokyo, Japan.
Yamashita T; Oncology Medical Science Department, Daiichi Sankyo Co., Ltd, Tokyo, Japan.
Sakajiri S; Juntendo Urayasu Hospital, Urayasu, Japan.
Yamamoto N; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2021 Jun; Vol. 112 (6), pp. 2361-2370. Date of Electronic Publication: 2021 May 02.
Typ publikacji :
Clinical Trial, Phase I; Journal Article
MeSH Terms :
Antineoplastic Agents/*administration & dosage
Indoles/*administration & dosage
Neoplasms/*drug therapy
Proto-Oncogene Proteins c-mdm2/*antagonists & inhibitors
Pyridines/*administration & dosage
Pyrrolidines/*administration & dosage
Small Molecule Libraries/*administration & dosage
Administration, Oral ; Adult ; Aged ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacokinetics ; Cohort Studies ; Drug Administration Schedule ; Humans ; Indoles/adverse effects ; Indoles/pharmacokinetics ; Japan ; Male ; Maximum Tolerated Dose ; Middle Aged ; Neoplasms/blood ; Neoplasms/metabolism ; Pyridines/adverse effects ; Pyridines/pharmacokinetics ; Pyrrolidines/adverse effects ; Pyrrolidines/pharmacokinetics ; Small Molecule Libraries/adverse effects ; Small Molecule Libraries/pharmacokinetics
Czasopismo naukowe
Tytuł :
Design, synthesis, and evaluation of N-benzylpyrrolidine and 1,3,4-oxadiazole as multitargeted hybrids for the treatment of Alzheimer's disease.
Autorzy :
Choubey PK; Pharmaceutical Chemistry Research Laboratory, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi 221005, India.
Tripathi A; Institute of Pharmaceutical Research, GLA University, Matura 281406, India.
Tripathi MK; Pharmaceutical Chemistry Research Laboratory, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi 221005, India.
Seth A; Aryakul College of Pharmacy & Research, Sitapur 2613303, India.
Shrivastava SK; Pharmaceutical Chemistry Research Laboratory, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi 221005, India. Electronic address: .
Pokaż więcej
Źródło :
Bioorganic chemistry [Bioorg Chem] 2021 Jun; Vol. 111, pp. 104922. Date of Electronic Publication: 2021 Apr 17.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Design*
Alzheimer Disease/*drug therapy
Cholinesterase Inhibitors/*pharmacology
Neuroprotective Agents/*pharmacology
Oxadiazoles/*pharmacology
Pyrrolidines/*pharmacology
Acetylcholinesterase/metabolism ; Alzheimer Disease/metabolism ; Amyloid beta-Peptides/antagonists & inhibitors ; Amyloid beta-Peptides/metabolism ; Animals ; Butyrylcholinesterase/metabolism ; Cholinesterase Inhibitors/chemical synthesis ; Cholinesterase Inhibitors/chemistry ; Disease Models, Animal ; Dose-Response Relationship, Drug ; Female ; Humans ; Male ; Maze Learning/drug effects ; Molecular Structure ; Neuroprotective Agents/chemical synthesis ; Neuroprotective Agents/chemistry ; Oxadiazoles/chemical synthesis ; Oxadiazoles/chemistry ; Peptide Fragments/antagonists & inhibitors ; Peptide Fragments/metabolism ; Pyrrolidines/chemical synthesis ; Pyrrolidines/chemistry ; Rats ; Rats, Wistar ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
Discovery of Nanomolar Melanocortin-3 Receptor (MC3R)-Selective Small Molecule Pyrrolidine Bis-Cyclic Guanidine Agonist Compounds Via a High-Throughput "Unbiased" Screening Campaign.
Autorzy :
Doering SR; Department of Medicinal Chemistry and Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Freeman K; Department of Medicinal Chemistry and Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Debevec G; Florida International University, Port St. Lucie, Florida 34987, United States.
Geer P; Florida International University, Port St. Lucie, Florida 34987, United States.
Santos RG; Nova Southeastern University, 3301 College Avenue, Fort Lauderdale, Florida 33314, United States.
Lavoi TM; Florida International University, Port St. Lucie, Florida 34987, United States.
Giulianotti MA; Florida International University, Port St. Lucie, Florida 34987, United States.
Pinilla C; Florida International University, Port St. Lucie, Florida 34987, United States.
Appel JR; Florida International University, Port St. Lucie, Florida 34987, United States.
Houghten RA; Florida International University, Port St. Lucie, Florida 34987, United States.
Ericson MD; Department of Medicinal Chemistry and Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Haskell-Luevano C; Department of Medicinal Chemistry and Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2021 May 13; Vol. 64 (9), pp. 5577-5592. Date of Electronic Publication: 2021 Apr 22.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Guanidine/*metabolism
Pyrrolidines/*chemistry
Receptor, Melanocortin, Type 3/*agonists
Algorithms ; Animals ; Drug Evaluation, Preclinical ; Energy Metabolism/drug effects ; Guanidine/analogs & derivatives ; Guanidine/pharmacology ; Guanidine/therapeutic use ; High-Throughput Screening Assays ; Humans ; Mice ; Mice, Knockout ; Protein Isoforms/agonists ; Protein Isoforms/genetics ; Protein Isoforms/metabolism ; Pyrrolidines/metabolism ; Pyrrolidines/pharmacology ; Pyrrolidines/therapeutic use ; Receptor, Melanocortin, Type 3/genetics ; Receptor, Melanocortin, Type 3/metabolism ; Small Molecule Libraries/chemistry ; Small Molecule Libraries/metabolism ; Small Molecule Libraries/pharmacology ; Small Molecule Libraries/therapeutic use ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
Pyrrolidine-based 3-deoxysphingosylphosphorylcholine analogs as possible candidates against neglected tropical diseases (NTDs): identification of hit compounds towards development of potential treatment of Leishmania donovani .
Autorzy :
Hassan AHE; Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.; Medicinal Chemistry Laboratory, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea.
Phan TN; Leishmania Research Laboratory, Institut Pasteur Korea, Seongnam-si, Korea.
Yoon S; Department of Life and Nanopharmaceutical Sciences, Kyung Hee University, Seoul, Republic of Korea.
Lee CJ; Department of Life and Nanopharmaceutical Sciences, Kyung Hee University, Seoul, Republic of Korea.
Jeon HR; Department of Life and Nanopharmaceutical Sciences, Kyung Hee University, Seoul, Republic of Korea.
Kim SH; Department of Life and Nanopharmaceutical Sciences, Kyung Hee University, Seoul, Republic of Korea.
No JH; Leishmania Research Laboratory, Institut Pasteur Korea, Seongnam-si, Korea.
Lee YS; Medicinal Chemistry Laboratory, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea.; Department of Life and Nanopharmaceutical Sciences, Kyung Hee University, Seoul, Republic of Korea.
Pokaż więcej
Źródło :
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2021 Dec; Vol. 36 (1), pp. 1922-1930.
Typ publikacji :
Journal Article
MeSH Terms :
Antiprotozoal Agents/*chemistry
Leishmania donovani/*drug effects
Phosphorylcholine/*chemistry
Pyrrolidines/*chemistry
Amide Synthases/metabolism ; Antiprotozoal Agents/pharmacology ; Drug Evaluation, Preclinical ; Humans ; Molecular Conformation ; Molecular Docking Simulation ; Palmitates/chemistry ; Pyrrolidines/pharmacology ; Sphingomyelins/chemistry ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
The Pharmacological Profile of Second Generation Pyrovalerone Cathinones and Related Cathinone Derivative.
Autorzy :
Kolaczynska KE; Division of Psychopharmacology Research, Department of Biomedicine, University Hospital Basel and University of Basel, 4031 Basel, Switzerland.
Thomann J; Division of Psychopharmacology Research, Department of Biomedicine, University Hospital Basel and University of Basel, 4031 Basel, Switzerland.
Hoener MC; Neuroscience Research, pRED, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.
Liechti ME; Division of Psychopharmacology Research, Department of Biomedicine, University Hospital Basel and University of Basel, 4031 Basel, Switzerland.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Jul 31; Vol. 22 (15). Date of Electronic Publication: 2021 Jul 31.
Typ publikacji :
Journal Article
MeSH Terms :
Alkaloids/*chemistry
Dopamine Plasma Membrane Transport Proteins/*antagonists & inhibitors
Norepinephrine Plasma Membrane Transport Proteins/*antagonists & inhibitors
Psychotropic Drugs/*chemistry
Pyrrolidines/*chemistry
Serotonin Plasma Membrane Transport Proteins/*metabolism
Alkaloids/pharmacology ; Biogenic Monoamines/metabolism ; Dopamine Plasma Membrane Transport Proteins/metabolism ; HEK293 Cells ; Humans ; Norepinephrine Plasma Membrane Transport Proteins/metabolism ; Protein Binding ; Psychotropic Drugs/pharmacology ; Pyrrolidines/pharmacology ; Quantitative Structure-Activity Relationship ; Serotonin Uptake Inhibitors/chemistry ; Serotonin Uptake Inhibitors/pharmacology
Czasopismo naukowe
Tytuł :
Structure-Activity Relationship Analysis of Cocrystallized Gliptin-like Pyrrolidine, Trifluorophenyl, and Pyrimidine-2,4-Dione Dipeptidyl Peptidase-4 Inhibitors.
Autorzy :
Tomovic K; Department of Pharmacy, Faculty of Medicine, University of Nis, Bulevar Dr Zorana Djindjica 81, 18000 Nis, Serbia.
Ilic BS; Department of Chemistry, Faculty of Medicine, University of Nis, Bulevar Dr Zorana Djindjica 81, 18000 Nis, Serbia.
Smelcerovic A; Department of Chemistry, Faculty of Medicine, University of Nis, Bulevar Dr Zorana Djindjica 81, 18000 Nis, Serbia.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2021 Jul 22; Vol. 64 (14), pp. 9639-9648. Date of Electronic Publication: 2021 Jun 30.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Dipeptidyl Peptidase 4/*metabolism
Dipeptidyl-Peptidase IV Inhibitors/*pharmacology
Pyrrolidines/*pharmacology
Crystallography, X-Ray ; Dipeptidyl-Peptidase IV Inhibitors/chemistry ; Dose-Response Relationship, Drug ; Humans ; Models, Molecular ; Molecular Structure ; Pyrrolidines/chemistry ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection.
Autorzy :
Dampalla CS; Department of Chemistry, Wichita State University, Wichita, KS 67260.
Zheng J; Department of Microbiology and Immunology, The University of Iowa, Iowa City, IA 52242.
Perera KD; Department of Diagnostic Medicine and Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506.
Wong LR; Department of Microbiology and Immunology, The University of Iowa, Iowa City, IA 52242.
Meyerholz DK; Department of Pathology, The University of Iowa, Iowa City, IA 52242.
Nguyen HN; Department of Chemistry, Wichita State University, Wichita, KS 67260.
Kashipathy MM; Protein Structure Laboratory, The University of Kansas, Lawrence, KS 66047.
Battaile KP; NYX, New York Structural Biology Center, Upton, NY 11973.
Lovell S; Protein Structure Laboratory, The University of Kansas, Lawrence, KS 66047.
Kim Y; Department of Diagnostic Medicine and Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506; .
Perlman S; Department of Microbiology and Immunology, The University of Iowa, Iowa City, IA 52242; .
Groutas WC; Department of Chemistry, Wichita State University, Wichita, KS 67260; .
Chang KO; Department of Diagnostic Medicine and Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506; .
Pokaż więcej
Źródło :
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2021 Jul 20; Vol. 118 (29).
Typ publikacji :
Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Antiviral Agents/*therapeutic use
COVID-19/*drug therapy
Coronavirus 3C Proteases/*antagonists & inhibitors
Coronavirus Papain-Like Proteases/*antagonists & inhibitors
Protease Inhibitors/*therapeutic use
Pyrrolidines/*therapeutic use
SARS-CoV-2/*drug effects
Angiotensin-Converting Enzyme 2/genetics ; Animals ; Antiviral Agents/chemical synthesis ; Antiviral Agents/chemistry ; Antiviral Agents/pharmacology ; COVID-19/pathology ; Coronavirus 3C Proteases/chemistry ; Coronavirus Papain-Like Proteases/chemistry ; Crystallography, X-Ray ; Deuterium ; Disease Models, Animal ; Drug Evaluation, Preclinical ; Female ; Lung/pathology ; Mice ; Mice, Transgenic ; Models, Molecular ; Molecular Structure ; Protease Inhibitors/chemical synthesis ; Protease Inhibitors/chemistry ; Protease Inhibitors/pharmacology ; Protein Conformation ; Pyrrolidines/chemistry ; SARS-CoV-2/enzymology ; Transgenes
Czasopismo naukowe
Tytuł :
Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit?
Autorzy :
Petrides PE; EPNET Center Munich, Hematology Oncology Center, University of Munich Medical School, Zweibrückenstr.2, 80331, Munich, Germany. .
Klein M; Klinikum Vest, Dorstener Strasse 151, 45657, Recklinghausen, Germany.
Schuhmann E; Homocysteine Laboratory, Labor Becker und Kollegen, Führichstr.70, 81671, Munich, Germany.
Torkler H; Genetics Laboratory, MVZ Eberhard, Brauhausstr.4, 44137, Dortmund, Germany.
Molitor B; Eurofin Laboratories, Rotthauser Str 19, 45879, Gelsenkirchen, Germany.
Loehr C; Department of Radiology, Klinikum Vest, Dorstener Strasse 151, 45657, Recklinghausen, Germany.
Obermeier Z; EPNET Center Munich, Hematology Oncology Center, University of Munich Medical School, Zweibrückenstr.2, 80331, Munich, Germany.
Beykirch MK; EPNET Center Munich, Hematology Oncology Center, University of Munich Medical School, Zweibrückenstr.2, 80331, Munich, Germany.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 Jul; Vol. 100 (7), pp. 1685-1693. Date of Electronic Publication: 2021 May 29.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
5-Aminolevulinate Synthetase/*antagonists & inhibitors
Acetylgalactosamine/*analogs & derivatives
Heme/*deficiency
Hyperhomocysteinemia/*etiology
Porphyria, Acute Intermittent/*drug therapy
Pyrrolidines/*therapeutic use
Acetylgalactosamine/adverse effects ; Acetylgalactosamine/therapeutic use ; Adult ; Arginine/therapeutic use ; Colitis/etiology ; Colon, Sigmoid/pathology ; Controlled Clinical Trials as Topic ; Drug Hypersensitivity/etiology ; Female ; Fibrosis ; Heme/analysis ; Heme/therapeutic use ; Hepatocytes/drug effects ; Hepatocytes/metabolism ; High-Throughput Nucleotide Sequencing ; Homocysteine/metabolism ; Humans ; Hydroxymethylbilane Synthase/blood ; Hydroxymethylbilane Synthase/genetics ; Male ; Models, Biological ; Pancreatitis/etiology ; Porphyria, Acute Intermittent/blood ; Porphyria, Acute Intermittent/complications ; Porphyria, Acute Intermittent/genetics ; Pyrrolidines/adverse effects
Czasopismo naukowe
Tytuł :
Influence of Plasdone S630 Ultra-an Improved Copovidone on the Processability and Oxidative Degradation of Quetiapine Fumarate Amorphous Solid Dispersions Prepared via Hot-Melt Extrusion Technique.
Autorzy :
Butreddy A; Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, Oxford, Mississippi, 38677, USA.
Sarabu S; Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, Oxford, Mississippi, 38677, USA.
Bandari S; Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, Oxford, Mississippi, 38677, USA.
Batra A; Ashland Specialty Ingredients, Wilmington, Delaware, 19808, USA.
Lawal K; Ashland Specialty Ingredients, Wilmington, Delaware, 19808, USA.
Chen NN; Ashland Specialty Ingredients, Wilmington, Delaware, 19808, USA.
Bi V; Ashland Specialty Ingredients, Wilmington, Delaware, 19808, USA.
Durig T; Ashland Specialty Ingredients, Wilmington, Delaware, 19808, USA.
Repka MA; Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, Oxford, Mississippi, 38677, USA. .; Pii Center for Pharmaceutical Technology, The University of Mississippi, University, Oxford, Mississippi, 38677, USA. .
Pokaż więcej
Źródło :
AAPS PharmSciTech [AAPS PharmSciTech] 2021 Jun 28; Vol. 22 (5), pp. 196. Date of Electronic Publication: 2021 Jun 28.
Typ publikacji :
Journal Article
MeSH Terms :
Hot Melt Extrusion Technology/*methods
Pharmaceutic Aids/*chemical synthesis
Povidone/*chemical synthesis
Pyrrolidines/*chemical synthesis
Quetiapine Fumarate/*chemical synthesis
Vinyl Compounds/*chemical synthesis
Calorimetry, Differential Scanning/methods ; Chemistry, Pharmaceutical/methods ; Drug Compounding/methods ; Hot Temperature ; Oxidation-Reduction ; Pharmaceutic Aids/pharmacokinetics ; Povidone/pharmacokinetics ; Pyrrolidines/pharmacokinetics ; Quetiapine Fumarate/pharmacokinetics ; Solubility ; Spectroscopy, Fourier Transform Infrared/methods ; Vinyl Compounds/pharmacokinetics
Czasopismo naukowe
Tytuł :
Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice.
Autorzy :
Ohya K; Department of Gastroenterology and Metabolism, Institute of Biomedical & Health Science, Hiroshima University, Hiroshima, Japan; Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Japan.
Imamura M; Department of Gastroenterology and Metabolism, Institute of Biomedical & Health Science, Hiroshima University, Hiroshima, Japan; Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Japan.
Teraoka Y; Department of Gastroenterology and Metabolism, Institute of Biomedical & Health Science, Hiroshima University, Hiroshima, Japan; Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Japan.
Uchida T; Department of Gastroenterology and Metabolism, Institute of Biomedical & Health Science, Hiroshima University, Hiroshima, Japan; Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Japan.
Fujino H; Department of Gastroenterology and Metabolism, Institute of Biomedical & Health Science, Hiroshima University, Hiroshima, Japan; Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Japan.
Nakahara T; Department of Gastroenterology and Metabolism, Institute of Biomedical & Health Science, Hiroshima University, Hiroshima, Japan; Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Japan.
Ono A; Department of Gastroenterology and Metabolism, Institute of Biomedical & Health Science, Hiroshima University, Hiroshima, Japan; Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Japan.
Murakami E; Department of Gastroenterology and Metabolism, Institute of Biomedical & Health Science, Hiroshima University, Hiroshima, Japan; Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Japan.
Yamauchi M; Department of Gastroenterology and Metabolism, Institute of Biomedical & Health Science, Hiroshima University, Hiroshima, Japan; Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Japan.
Kawaoka T; Department of Gastroenterology and Metabolism, Institute of Biomedical & Health Science, Hiroshima University, Hiroshima, Japan; Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Japan.
Miki D; Department of Gastroenterology and Metabolism, Institute of Biomedical & Health Science, Hiroshima University, Hiroshima, Japan; Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Japan.
Tsuge M; Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Japan; Natural Science Center for Basic Research and Development, Hiroshima University, Hiroshima, Japan.
Abe-Chayama H; Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Japan; Center for Medical Specialist Graduate Education and Research, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Hayes CN; Department of Gastroenterology and Metabolism, Institute of Biomedical & Health Science, Hiroshima University, Hiroshima, Japan; Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Japan.
Aikata H; Department of Gastroenterology and Metabolism, Institute of Biomedical & Health Science, Hiroshima University, Hiroshima, Japan; Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Japan.
Ishida Y; Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Japan; PhoenixBio Co., Ltd., Higashihiroshima, Japan.
Tateno C; Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Japan; PhoenixBio Co., Ltd., Higashihiroshima, Japan.
Song H; Laboratory of Tumor Viruses, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.
Miyayama Y; Laboratory of Tumor Viruses, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.
Hijikata M; Laboratory of Tumor Viruses, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.
Chayama K; Department of Gastroenterology and Metabolism, Institute of Biomedical & Health Science, Hiroshima University, Hiroshima, Japan; Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Japan; Institute of Physical and Chemical Research (RIKEN) Center for Integrative Medical Sciences, Yokohama, Japan. Electronic address: .
Pokaż więcej
Źródło :
Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2021 Jun 25; Vol. 559, pp. 78-83. Date of Electronic Publication: 2021 Apr 29.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Resistance, Viral*
Antiviral Agents/*pharmacology
Benzimidazoles/*pharmacology
Hepacivirus/*drug effects
Hepatitis C/*drug therapy
Pyrrolidines/*pharmacology
Animals ; Antiviral Agents/therapeutic use ; Benzimidazoles/therapeutic use ; Hepacivirus/genetics ; Hepatitis C/virology ; Hepatocytes/virology ; Humans ; Male ; Mice ; Mice, SCID ; Mutation/drug effects ; Pyrrolidines/therapeutic use
Czasopismo naukowe
Tytuł :
Prospective Drug Candidates as Human Multidrug Transporter ABCG2 Inhibitors: an In Silico Drug Discovery Study.
Autorzy :
Ibrahim MAA; Computational Chemistry Laboratory, Chemistry Department, Faculty of Science, Minia University, Minia, Egypt. .
Badr EAA; Computational Chemistry Laboratory, Chemistry Department, Faculty of Science, Minia University, Minia, Egypt.
Abdelrahman AHM; Computational Chemistry Laboratory, Chemistry Department, Faculty of Science, Minia University, Minia, Egypt.
Almansour NM; Department of Biology, College of Science, University of Hafr Al Batin, Hafr Al Batin, Saudi Arabia.
Shawky AM; Science and Technology Unit (STU), Umm Al-Qura University, Makkah, Saudi Arabia.
Mekhemer GAH; Computational Chemistry Laboratory, Chemistry Department, Faculty of Science, Minia University, Minia, Egypt.
Alrumaihi F; Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia.
Moustafa MF; Department of Biology, College of Science, King Khalid University, Abha, Saudi Arabia.; Department of Botany & Microbiology, Faculty of Science, South Valley University, Qena, Egypt.
Atia MAM; Molecular Genetics and Genome Mapping Laboratory, Genome Mapping Department, Agricultural Genetic Engineering Research Institute (AGERI), Agricultural Research Center (ARC), Giza, Egypt. .
Pokaż więcej
Źródło :
Cell biochemistry and biophysics [Cell Biochem Biophys] 2021 Jun; Vol. 79 (2), pp. 189-200. Date of Electronic Publication: 2021 May 05.
Typ publikacji :
Journal Article
MeSH Terms :
ATP Binding Cassette Transporter, Subfamily G, Member 2/*antagonists & inhibitors
Benzimidazoles/*chemistry
Bridged Bicyclo Compounds, Heterocyclic/*chemistry
Fluorenes/*chemistry
Neoplasm Proteins/*antagonists & inhibitors
Pyrrolidines/*chemistry
Sulfonamides/*chemistry
ATP Binding Cassette Transporter, Subfamily G, Member 2/metabolism ; Benzimidazoles/metabolism ; Binding Sites ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Bridged Bicyclo Compounds, Heterocyclic/metabolism ; Databases, Chemical ; Drug Discovery ; Drug Resistance, Neoplasm ; Female ; Fluorenes/metabolism ; Humans ; Hydrogen Bonding ; Molecular Docking Simulation ; Molecular Dynamics Simulation ; Neoplasm Proteins/metabolism ; Protein Binding ; Pyrrolidines/metabolism ; Sulfonamides/metabolism ; Thermodynamics
Czasopismo naukowe
Tytuł :
The Pre-treatment Lymphocyte-to-Monocyte Ratio Predicts Efficacy in Metastatic Colorectal Cancer Treated With TAS-102 and Bevacizumab.
Autorzy :
Kuramochi H; Department of Chemotherapy, Tokyo Women's Medical University, Yachiyo Medical Center, Yachiyo, Japan.
Yamada T; Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo, Japan; .
Yoshida Y; Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
Matsuda A; Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo, Japan.
Kamiyama H; Department of Coloproctological Surgery, Juntendo University Faculty of Medicine, Tokyo, Japan.
Kosugi C; Department of Surgery, Teikyo University Chiba Medical Center, Ichihara, Japan.
Ishibashi K; Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
Fukazawa A; Department of Gastroenterological Surgery, Iwata City Hospital, Iwata, Japan.
Ihara K; First Department of Surgery, Dokkyo Medical University, Mibu, Japan.
Sonoda H; Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo, Japan.
Yoshimatsu K; Department of Digestive Surgery, Kawasaki Medical School, Kurashiki, Japan.
Yoshida H; Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo, Japan.
Hasegawa S; Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
Sakamoto K; Department of Coloproctological Surgery, Juntendo University Faculty of Medicine, Tokyo, Japan.
Ishida H; Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
Koda K; Department of Surgery, Teikyo University Chiba Medical Center, Ichihara, Japan.
Pokaż więcej
Corporate Authors :
TAS CC3 Study Group
Źródło :
Anticancer research [Anticancer Res] 2021 Jun; Vol. 41 (6), pp. 3131-3137.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents, Immunological/*therapeutic use
Bevacizumab/*therapeutic use
Colorectal Neoplasms/*drug therapy
Lymphocytes/*pathology
Monocytes/*pathology
Neoplasm Metastasis/*drug therapy
Pyrrolidines/*therapeutic use
Thymine/*therapeutic use
Trifluridine/*therapeutic use
Aged ; Antineoplastic Agents, Immunological/administration & dosage ; Bevacizumab/administration & dosage ; Colorectal Neoplasms/pathology ; Drug Combinations ; Female ; Humans ; Male ; Middle Aged ; Pyrrolidines/administration & dosage ; Thymine/administration & dosage ; Trifluridine/administration & dosage
Czasopismo naukowe
Tytuł :
Dose-escalation strategy in refractory metastatic colorectal cancer: A change in terms of cost-effectiveness.
Autorzy :
Giuliani J; Department of Oncology, Mater Salutis Hospital, Legnago, Italy.
Fiorica F; Department of Radiation Oncology, Mater Salutis Hospital, Legnago, Italy.
Ponturo G; Department of Pharmacology, Mater Salutis Hospital, Legnago, Italy.
Azzurro M; Department of Gastroenterology, Mater Salutis Hospital, Legnago, Italy.
Ruzzenente A; Department of Surgery, General and Hepatobiliary Surgery, University Hospital G.B. Rossi, University and Hospital Trust of Verona, Verona, Italy.
Bonetti A; Department of Oncology, Mater Salutis Hospital, Legnago, Italy.
Pokaż więcej
Źródło :
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2021 Jun; Vol. 27 (4), pp. 974-977. Date of Electronic Publication: 2021 Feb 04.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Colorectal Neoplasms/*drug therapy
Colorectal Neoplasms/*economics
Cost-Benefit Analysis/*methods
Drug Costs/*trends
Phenylurea Compounds/*economics
Pyridines/*economics
Pyrrolidines/*economics
Thymine/*economics
Trifluridine/*economics
Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/economics ; Dose-Response Relationship, Drug ; Drug Combinations ; Humans ; Phenylurea Compounds/administration & dosage ; Pyridines/administration & dosage ; Pyrrolidines/administration & dosage ; Thymine/administration & dosage ; Trifluridine/administration & dosage
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies